SLC-391

DRUG3 trials

Sponsors

SignalChem Lifesciences Corporation

Conditions

Food-drug InteractionLung Cancer MetastaticLung Cancer Stage IVLung Cancer, Nonsmall CellSolid Tumor

Phase 1

Safety Study of SLC-391 in Subjects With Solid Tumors

CompletedNCT03990454

SignalChem Lifesciences CorporationSolid Tumor

Start: 2019-09-17End: 2023-06-30Updated: 2023-08-18

Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects

CompletedNCT05278845

SignalChem Lifesciences CorporationFood-drug Interaction

Start: 2022-02-12End: 2022-06-14Updated: 2022-08-01

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

TerminatedNCT05860296

SignalChem Lifesciences CorporationLung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV

Start: 2023-05-31End: 2025-12-01Updated: 2025-12-18

Related Papers

First-in-Human Phase I Clinical Trial of SLC-391, a Novel and Selective AXL Inhibitor, in Patients with Advanced Solid Tumours.

2025-12-17